Grifols SA ADR [NASDAQ: GRFS] closed the trading session at $6.78. The company report on February 14, 2024 at 3:16 AM that Grifols announces positive topline phase 3 fibrinogen clinical trial results. In the AdFIrst study, Biotest’s fibrinogen concentrate (FC), BT524, met the primary endpoint,
Grifols SA ADR [NASDAQ: GRFS] price plunged by -9.15 percent to reach at -$0.58. The company report on February 14, 2024 at 3:16 AM that Grifols announces positive topline phase 3 fibrinogen clinical trial results. In the AdFIrst study, Biotest’s fibrinogen concentrate (FC), BT524, met
Grifols SA ADR [NASDAQ: GRFS] loss -11.35% or -0.7 points to close at $5.47 with a heavy trading volume of 7574372 shares. The company report on February 14, 2024 at 3:16 AM that Grifols announces positive topline phase 3 fibrinogen clinical trial results. In the
Grifols SA ADR [NASDAQ: GRFS] loss -19.59% on the last trading session, reaching $7.51 price per share at the time. The company report on February 14, 2024 at 3:16 AM that Grifols announces positive topline phase 3 fibrinogen clinical trial results. In the AdFIrst study,
© 2024, Powered by Smart TechOne
